Clinical Trials
36 trialsEvaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Brown University
OPTIMISE
Pfizer
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ludwig Institute for Cancer Research
NIVOSWITCH
AIO-Studien-gGmbH
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
TAURUS
AVEO Pharmaceuticals, Inc.
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Celgene
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Indiana University
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Taipei Veterans General Hospital, Taiwan
ADAPT
Argos Therapeutics
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
SUNRISES
Associació per a la Recerca Oncologica, Spain
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
Amsterdam UMC, location VUmc
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Hoosier Cancer Research Network
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The Methodist Hospital Research Institute
Multimodality Phase II Study in Prostate Cancer
Duke University
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
University Health Network, Toronto
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Medical University of South Carolina
PREINSUT
Assistance Publique - Hôpitaux de Paris
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
University of Michigan Rogel Cancer Center
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
Pfizer
SUN 1120
Pfizer
Cost Effectiveness Of Sunitinib In Central America And Caribbean
Pfizer
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Genentech, Inc.
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
Wyeth is now a wholly owned subsidiary of Pfizer